Latest news about Alpa Laboratories
Alpa Laboratories
66.84
-0.64(-0.95%)
Company Performance:
View Company Insights1D-0.95%
1M-1.05%
6M-1.91%
1Y-35.56%
5Y+37.11%
More news about Alpa Laboratories
11Apr 26
Alpa Laboratories Appoints Ms. Yashoda Patidar as Company Secretary and Compliance Officer
Alpa Laboratories Ltd. has appointed Ms. Yashoda Patidar as Company Secretary and Compliance Officer effective April 11, 2026. The Board of Directors approved the appointment based on Nomination and Remuneration Committee recommendations. Ms. Patidar is an Associate Member of the Institute of Company Secretaries of India with Membership No. A76970 and holds no shareholding in the company.
10Apr 26
Alpa Laboratories Clarifies No Price Sensitive Information Following Stock Exchange Inquiry
Alpa Laboratories Ltd responded to stock exchange inquiry about price movement, clarifying no undisclosed price sensitive information exists. Director Mahendra Singh Chawla confirmed on April 9, 2026, that no events or announcements are planned that would affect company performance or stock price. The clarification was issued under Regulation 30 compliance requirements.
09Mar 26
Alpa Laboratories Reports Promoter Share Transfer Under SEBI SAST Regulations
Alpa Laboratories Limited has completed a promoter group share transfer involving 21,940 equity shares (0.10% of share capital) transferred as a gift from Bakulesh Chandulal Shah HUF to Mr. Vinit Shah on March 7, 2026. The transaction was conducted as an off-market inter se transfer between immediate relatives under SEBI SAST Regulations, with comprehensive disclosures filed under Regulations 10(6), 29(1), and 29(2). The company confirmed no net change in total promoter group shareholding, maintaining compliance with regulatory requirements.
25Feb 26
Alpa Laboratories Company Secretary Ms. Srashiti Chopra Resigns Due to Personal Reasons
Alpa Laboratories Limited announced the resignation of Company Secretary and Compliance Officer Ms. Srashiti Chopra, effective March 25, 2026. The resignation, submitted on February 25, 2026, was due to personal reasons. The company has notified both NSE and BSE in compliance with SEBI regulations, with Ms. Chopra committed to ensuring smooth transition of responsibilities during the notice period.
11Feb 26
Alpa Laboratories Reports Q3FY26 Results with Revenue Growth of 13.5% YoY
Alpa Laboratories Limited reported Q3FY26 results with revenue growth of 13.5% to Rs 2,967.12 lacs, but net profit declined 78.9% to Rs 187.48 lacs. Nine-month revenue grew 2.6% to Rs 7,441.40 lacs while profit fell 36.5% to Rs 1,375.20 lacs. The pharmaceutical company operates in drugs and chemicals segment.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
1,990.50
(-0.53%)
8,056.00
(+2.82%)
5,122.80
(+5.15%)
1,473.20
(+0.46%)
1,126.80
(+1.05%)
2,415.00
(-0.26%)
2,469.60
(-4.13%)
1,816.20
(+1.96%)
1,148.10
(+0.29%)
1,580.20
(+0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
